Status:
COMPLETED
Ginkgo Biloba Extract in the Treatment of Schizophrenia
Lead Sponsor:
Beijing HuiLongGuan Hospital
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
We investigated the effects of Ginkgo biloba extract on the symptoms and cognitive functioning in patients with schizophrenia
Detailed Description
Objective: This study aimed to evaluate the effect of Ginkgo biloba extract in the treatment of symptoms and cognitive functioning in 200? chronic patients with schizophrenia Methods: 1. Clinical Tr...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia by two senior psychiatrists
- Between 18 and 60 years and Han Chinese
- Duration of symptoms at least 12 months
- Current psychotic symptoms of moderate severity
Exclusion
- A Diagnostic and Statistical Manual of Mental Disorders IV Axis I diagnosis other than schizophrenia
- Documented disease of physical diseases including, but not limited to stroke, tumor, Parkinson's disease, Huntington's disease, seizure, epilepsy, history of brain trauma；
- Pregnant or breast-feeding female'
- Subjects who suffered from alcohol or illegal durg abuse/dependence
Key Trial Info
Start Date :
May 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 15 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05258123
Start Date
May 15 2017
End Date
August 15 2018
Last Update
February 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing HuiLongGuan Hospital
Beijing, China, 100096